References
- Hehlmann R, Anger B, Messerer D, et al. Chemotherapy of CML. Progress report of the German multicenter study of busulphan versus hydroxyurea versus interferon alpha October 1987. Onkologie 1988; 11: 25–9
- Koeffler H P, Golde DW. Chronic myelogenous leukemia: new concepts. N Engl J Med 1981; 304: 1269–74
- Coleman M, Silver R T, Pajak T F, et al. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies. Blood 1980; 55: 29–36
- Cancer incidence in Sweden. National Board of Health and Welfare. 1985
- Talpaz M, Kantarjian H M, McCredie K, Trujillo J M, Keating M J, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alfa A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–9
- Alimena G, Morra E, Lazzarino M, et al. Interferon alpha 2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–7
- Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
- Cantell K, Hirvonen S, Koistinen V. Partial purification of human leucocyte interferon on a large scale. Methods Enzymol 1981; 78: 499–505
- Armstrong J. Semimicro, dye-binding assay for rabbit interferon. Apply Microbiol 1971; 21: 723–5
- National Institute for Biological Standards and Control. Holly Hill, Hampstead, London 1986
- Figlin R, Itri L. Anti-interferon antibodies: a perspective. Semin Hematol 1988; 25(Suppl 3)9–15
- Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989; 72: 350–6
- von Wussow P, Freund M, Block B, et al. Clinical significance of anti-interferon-a antibody titres during interferon therapy. Lancet 1987; 2: 635
- Freund M, von Wussow P, Knüver-Hopf J, et al. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. Blut 1988; 57: 311–5